Diana E. Roopchand

Dr. Diana E. Roopchand


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
LZLi Zhang
Li Zhang
RCRachel N. Carmody
Rachel N. Carmody
HKHetal M. Kalariya
Hetal M. Kalariya
RDRocio M. Duran
Rocio M. Duran
KMKristin Moskal
Kristin Moskal
DRDiana E. Roopchand
Diana E. Roopchand

28 October 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
J. Abraham Domínguez AvilaJ. Abraham Domínguez Avila
J. Abraham Domínguez Avila
JVJose A. Villa-Rodriguez
Jose A. Villa-Rodriguez
MMMarcelino Montiel-Herrera
Marcelino Montiel-Herrera
RPRamón Pacheco-Ordaz
Ramón Pacheco-Ordaz
DRDiana E. Roopchand
Diana E. Roopchand
Gustavo A. González-AguilarGustavo A. González-Aguilar
Gustavo A. González-Aguilar

1 June 2023 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
KTKevin M. Tveter
Kevin M. Tveter
EMEsther Mezhibovsky
Esther Mezhibovsky
YWYue Wu
Yue Wu
DRDiana E. Roopchand
Diana E. Roopchand

14 June 2021 in Frontiers in Nutrition
Verified
Journal Article
Open access
EMEsther Mezhibovsky
Esther Mezhibovsky
KKKim A. Knowles
Kim A. Knowles
QHQiyue He
Qiyue He
KSKe Sui
Ke Sui
Kevin M TveterKevin M Tveter
Kevin M Tveter
DRDiana E. Roopchand
Diana E. Roopchand
A Western Diet (WD) low in fiber but high in fats and sugars contributes to obesity and non-alcoholic fatty liver disease (NAFLD). Supplementation with grape polyphenols (GPs) rich in B-type proanthocyanidins (PACs) can attenuate symptoms of cardiometabolic disease and alter the gut microbiota and its metabolites. We hypothesized that GP-mediated metabolic improvements would correlate with altered microbial metabolites such as short chain fatty acids (SCFAs). To more closely mimic a WD, C57BL/6J male mice were fed a low-fiber diet high in sucrose and butterfat along with 20% sucrose water to represent sugary beverages. This WD was supplemented with 1% GPs (WD-GP) to investigate the impact of GPs on energy balance, SCFA profile, and intestinal metabolism. Compared to WD-fed mice, the WD-GP group had higher lean mass along with lower fat mass, body weight, and hepatic steatosis despite consuming more calories from sucrose water. Indirect and direct calorimetry revealed that reduced adiposity in GP-supplemented mice was likely due to their greater energy expenditure, which resulted in lower energy efficiency compared to WD-fed mice. GP-supplemented mice had higher abundance of Akkermansia muciniphila, a gut microbe reported to increase energy expenditure. Short chain fatty acid measurements in colon content revealed that GP-supplemented mice had lower concentrations of butyrate, a major energy substrate of the distal intestine, and reduced valerate, a putrefactive SCFA. GP-supplementation also resulted in a lower acetate:propionate ratio suggesting reduced hepatic lipogenesis. Considering the higher sucrose consumption and reduced butyrate levels in GP-supplemented mice, we hypothesized that enterocytes would metabolize glucose and fructose as a replacement energy source. Ileal mRNA levels of glucose transporter-2 (GLUT2, SLC2A2) were increased indicating higher glucose and fructose uptake. Expression of ketohexokinase (KHK) was increased in ileum tissue suggesting increased fructolysis. A GP-induced increase in intestinal carbohydrate oxidation was supported by: (1) increased gene expression of duodenal pyruvate dehydrogenase (PDH), (2) a decreased ratio of lactate dehydrogenase a (LDHa): LDHb in jejunum and colon tissues, and (3) decreased duodenal and colonic lactate concentrations. These data indicate that GPs protect against WD-induced obesity and hepatic steatosis by diminishing portal delivery of lipogenic butyrate and sugars due to their increased intestinal utilization.

7 August 2020 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
Kevin M TveterKevin M Tveter
Kevin M Tveter
JVJose A Villa-Rodriguez
Jose A Villa-Rodriguez
ACAlrick J Cabales
Alrick J Cabales
LZLi Zhang
Li Zhang
FBFiona G Bawagan
Fiona G Bawagan
DRDiana E. Roopchand
Diana E. Roopchand
Introduction: Bile acid (BA) biotransformation by gut bacteria impacts BA profile and signaling to nuclear receptors, such as the farnesoid X receptor (FXR) regulating glucose metabolism. Altered BA-FXR signaling was therefore investigated as a potential mechanism linking polyphenol-induced gut bacterial changes and improved glucose metabolism. Research design and methods: Diabetic db/db were fed low-fat diet (LFD) or LFD supplemented with a proanthocyanidin-rich extract of grape polyphenols (LFD-GP) for 4 weeks. Metabolic phenotypes, serum BAs, gut microbiota composition, and gene expression markers relevant to gut barrier and glucose metabolism were assessed. Gut organoids were used to investigate effects of individual BAs on ileal FXR activity. Results: Compared with LFD-fed controls, GP supplemented db/db mice showed improved glucose metabolism, decreased relative abundance of gut bacteria associated with production of secondary BAs (SBAs), and depleted serum levels of SBAs taurohyodeoxycholic acid (THDCA), ω-muricholic acid (ωMCA), and tauro-ω-muricholic acid (TωMCA). Serum levels of primary BAs (PBAs) increased, consistent with higher gene expression of PBA synthesis enzyme Cyp7a1. GP-induced BA changes associated with FXR inhibition as evidenced by reduced expression of FXR-responsive genes Shp, Fgf15, and Fabp6 in ileum tissue as well as hepatic Shp, which negatively regulates PBA synthesis. GP treatment did not affect expression of hepatic Fxr or expression of Abcb11, Slc51b, and Obp2a genes controlling BA transport. Ceramide biosynthesis genes Smpd3, Sptlc2, and Cers4 were decreased in liver and intestine suggesting lower tissue ceramides levels may contribute to improved glucose metabolism. THDCA, ωMCA, and TωMCA behaved as FXR agonists in ileal organoid experiments; therefore, their depletion in serum of GP-supplemented db/db and wild type (WT) mice was consistent with FXR inhibition. Conclusion: These data suggest that by altering the gut microbiota, GPs modify BA-FXR signaling pathways to promote glucoregulation.

17 November 2025 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
Michael Leonidas ChikindasMichael Leonidas Chikindas
Michael Leonidas Chikindas
DRDiana E. Roopchand
Diana E. Roopchand
STSantosh Kumar Tiwari
Santosh Kumar Tiwari
LSLiubov S. Sichel
Liubov S. Sichel
MKMukund V. Karwe
Mukund V. Karwe
STSvetoslav Todorov
Svetoslav Todorov
Postbiotics have emerged as a promising alternative to live probiotics, offering comparable health benefits while overcoming challenges related to safety, stability, and shelf life. This review provides a comprehensive overview of the current state of postbiotic research, beginning with updated definitions and the rationale for transitioning from live microbial formulations to inanimate postbiotics. We examine the diverse mechanisms by which postbiotics modulate host physiology, including enhancement of epithelial barrier function, immunomodulation, systemic metabolic regulation, neuroactive effects, anti‐inflammatory activities, and anticancer properties. Detailed discussions highlight how bioactive components—such as bacteriocins, exopolysaccharides (EPS), short‐chain fatty acids (SCFA), and specific proteins (e.g., Amuc_1100 and P9 from Akkermansia muciniphila )—mediate these effects through complex cellular signaling pathways and host‐microbe interactions. Furthermore, we review the antimicrobial potential of postbiotic formulations, emphasizing their role in controlling pathogenic and spoilage microorganisms. Various methods for microbial inactivation are discussed, ranging from conventional thermal techniques (e.g., pasteurization and ohmic heating) to non‐thermal approaches (e.g., ultrasonication, ionizing radiation, and ultraviolet light), as well as innovative hybrid methods that combine chemical, physical, and enzymatic treatments. These strategies not only ensure the complete inactivation of live microorganisms but also preserve the integrity and bioactivity of postbiotic compounds. Comparative analyses of live probiotics versus postbiotics reveal that inactivated formulations can deliver similar or even enhanced health benefits, with superior safety profiles and improved quality control. The review concludes by addressing current challenges in standardizing postbiotic definitions and production processes and by outlining future research directions necessary to unlock their full potential in clinical, nutritional, and biotechnological applications.